EVER Neuro Pharma GmbH
🇦🇹Austria
- Country
- 🇦🇹Austria
- Ownership
- Subsidiary
- Established
- 1934-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.everpharma.com
Clinical Trials
14
Active:4
Completed:5
Trial Phases
4 Phases
Phase 1:1
Phase 2:3
Phase 3:1
+1 more phases
Drug Approvals
7
SFDA:3
CIMA_AEMPS:3
PHILIPPINES:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 4
4 (44.4%)Phase 2
3 (33.3%)Phase 1
1 (11.1%)Phase 3
1 (11.1%)Cerebrolysin in CADASIL
Phase 2
Recruiting
- Conditions
- Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Target Recruit Count
- 30
- Registration Number
- 2024-513828-42-00
- Locations
- 🇨🇿
Fakultni Nemocnice V Motole, Prague, Czechia
IMPULSE - StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE
Phase 2
Terminated
- Conditions
- Chronic StrokeSubacute Stroke
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2022-07-28
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Target Recruit Count
- 4
- Registration Number
- NCT04124367
- Locations
- 🇦🇹
Klinik Pirawarth, Bad Pirawarth, Austria
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
- First Posted Date
- 2018-03-29
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Target Recruit Count
- 1851
- Registration Number
- NCT03480698
- Locations
- 🇦🇹
Landesklinikum Amstetten, Amstetten, Austria
🇦🇹Krankenhaus der Barmherzigen Brüder Eisenstadt, Eisenstadt, Austria
🇦🇹Universitätsklinik Innsbruck, Innsbruck, Austria
Cerebrolysin REGistry Study in Stroke
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Target Recruit Count
- 1823
- Registration Number
- NCT02541227
- Locations
- 🇦🇹
AKH Linz, Linz, Austria
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Ever Neuro Pharma GmbH
- Registration Number
- NCT01822951
- Locations
- 🇦🇹
AKh Allgemeines Krankenhaus der Stadt Linz GmbH, Linz, Austria
- Prev
- 1
- 2
- Next
News
No news found